Frequently Asked Question
The global rapid influenza diagnostic test (RIDT) market was valued at USD 1.2 Billion in 2022.
The rapid influenza diagnostic test (RIDT) market is expected to grow at a CAGR of 7.5% between 2023 and 2030, reaching USD 1.99 Billion in 2030.
Hospitals & clinics are the leading segment by end-user, holding over 40% share in terms of value in 2022.
The laboratories segment will post the highest CAGR in the projected period.
Asia Pacific is fueling the rapid growth of the rapid influenza diagnostic test (RIDT) industry, with an over one-third share in 2022.
The top market players are Alere Inc, DiaSorin, Roche Diagnostics, and SA Scientific Ltd. Other major players include Quidel Corporation, Meridian Bioscience Inc, BD, Thermo Fisher Scientific, and Luminex Corporation.
The main market drivers are the rising prevalence of influenza, the shift towards point-of-care testing, technological improvements, rising regulatory approvals, and the impact of the COVID-19 pandemic.
The major market restraints are the potential for false negatives or positives in test results, regulatory challenges and approvals, competition from alternative diagnostic methods, and cost-effectiveness concerns.
The major market opportunities of the rapid influenza diagnostic test (RIDT) industry lie in emerging economies with expanding healthcare infrastructure, the development of advanced RIDTs, integration into telemedicine and remote healthcare platforms, strategic collaborations, and expansion into adjacent markets such as infectious disease testing and point-of-care diagnostics.